Business Wire - Wednesday January 6, 1999

Separately, the jury cleared Jack Aronowitz, individually, on the issue of business interference, but found against him for misappropriation of trade secrets and assessed damages at $500,000. In the event any individual damages are ultimately required to be paid, the Company will indemnify Jack Aronowitz.

TOTAL DAMAGES OF MORE THAN $3.1 MILLION WERE ASSESSED AGAINST THE OTHER CORPORATE AND INDIVIDUAL DEFENDANTS IN THIS CASE WHICH HAVE NO BEARING WHATSOEVER ON TCPI.

"This was a complex case and we are pleased with the jury's findings in favor of TCPI on the trade secrets issue," said Jay E. Eckhaus, TCPI's general counsel. "We will ask the Court to set aside the decision against TCPI on business interference, as well as the finding against Mr. Aronowitz as an individual. In the event they are not reversed, TCPI's attorneys will immediately begin the appeal process," Eckhaus added.

Copies of this and other news releases may be obtained free of charge by calling TCPI's automated fax service at (800) 464-9217. Additional information on the Company can be obtained from TCPI's Web site at http://www.techchem.com. TCPI, with headquarters in Pompano Beach, Florida, is primarily engaged in the design, development, manufacture and marketing of a wide-range of point-of-care medical diagnostic products for use at home, in physician offices, and other healthcare locations.

Information in this press release, including any information incorporated by reference herein, includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and is subject to the safe-harbor created by such sections. The Company's actual results may differ significantly from the results discussed in such forward-looking statements.

Statements regarding future products, future prospects, business plans and strategies, future revenues and revenue sources, future liquidity and capital resources, health care market directions, future acceptance of the Company's products, possible recommendations of health care professionals or governmental agencies regarding use of diagnostic products, possible growth in markets for at-home diagnostic testing, as well as other statements contained in this report that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future, and similar statements are forward looking statements. These statements are based upon assumptions and analyses made by the Company in light of current conditions, future developments and other factors the Company believes are appropriate in the circumstances, or information obtained from third parties and are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that forward-looking statements are not guarantees of future performance and that actual results might differ materially from those suggested or projected in the forward-looking statements. Some of the factors that may cause actual future events to differ from those predicted or assumed include: future advances in technologies and medicine; the uncertainties of health care reform; risks related to the early stage of the Company's existence and its products' development; the Company's ability to execute on its business plans; the Company's dependence on outside parties such as its key customers and alliance partners; competition from major pharmaceutical, medical and diagnostic companies; risks and expense of government regulation and affects of changes in regulation (including risks associated with obtaining requisite governmental approvals for the Company's products); the limited experience of the Company in manufacturing and marketing products; uncertainties connected with product liability exposure and insurance; risks associated with growth and expansion; risks associated with obtaining patents and other protections on intellectual property; results of litigation and appeals; uncertainties in availability of expansion capital in the future and other risks associated with capital markets, as well as those listed in the Company's other press releases and in its Annual report on Form 10-K for the fiscal year ended December 31, 1997 and other filings with the Securities and Exchange Commission. The Company may determine to discontinue or delay the development of any or all of its products under development at any time. For a complete description of the Company's products and business, see Part I, Item 1 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1997.

Contact: Technical Chemicals & Products, Pompano Beach Howard A. Goldman Vice President/Investor Relations Phone: (954) 979-0400 E-mail: invrel@techchem.com or Weber/RBB Karen Janson or Sandy Baksys Phone: (305) 448-7450
990106
BW990102

Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .